VAXCYTE, INC. Increase (Decrease) in Prepaid Expense and Other Assets
VAXCYTE, INC. (PCVX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$4.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$13.67M, a 305.07% decline year-over-year.
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $8.74M, a 483.26% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $9.55M, a 189.63% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$915.00K, a 261.66% decline year-over-year.
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $16.80M, a 188.31% increase from fiscal 2024.
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $5.83M.
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$17.87M.
- VAXCYTE, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$433.00K, a 105.88% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.93M 10-Q · filed 2026-08-05 | $4.62M derived: sum of 3 quarters · filed 2026-08-05 | $3.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $8.74M 10-Q · filed 2026-05-06 | $18.29M derived: sum of 2 quarters · filed 2026-05-06 | $17.38M derived: sum of 3 quarters · filed 2026-05-06 | $24.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $9.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.63M derived: sum of 2 quarters · filed 2026-02-24 | $15.30M derived: sum of 3 quarters · filed 2026-08-05 | $16.80M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$915.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.75M derived: sum of 2 quarters · filed 2026-08-05 | $7.25M 10-Q · filed 2025-11-04 | $10.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $6.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.17M 10-Q · filed 2026-08-05 | $11.46M derived: sum of 3 quarters · filed 2026-08-05 | $12.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-06 | $4.80M derived: sum of 2 quarters · filed 2026-05-06 | $5.36M derived: sum of 3 quarters · filed 2026-05-06 | $2.37M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.86M derived: sum of 2 quarters · filed 2026-02-24 | $869.00K derived: sum of 3 quarters · filed 2026-02-24 | $5.83M 10-K · filed 2026-02-24 |
| 2024-09-30 | $566.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.43M derived: sum of 2 quarters · filed 2025-11-04 | $2.53M 10-Q · filed 2025-11-04 | -$12.91M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.96M 10-Q · filed 2025-08-06 | -$13.47M derived: sum of 3 quarters · filed 2026-02-24 | -$20.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $4.96M 10-Q · filed 2025-05-07 | -$10.48M derived: sum of 2 quarters · filed 2026-02-24 | -$17.61M derived: sum of 3 quarters · filed 2026-02-24 | -$17.61M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$15.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$22.56M derived: sum of 2 quarters · filed 2026-02-24 | -$22.57M derived: sum of 3 quarters · filed 2026-02-24 | -$17.87M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$7.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$7.13M derived: sum of 2 quarters · filed 2024-11-05 | -$2.43M 10-Q · filed 2024-11-05 | -$12.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.69M 10-Q · filed 2024-08-06 | $7.11M derived: sum of 3 quarters · filed 2025-02-25 | $5.28M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $4.70M 10-Q · filed 2024-05-08 | $7.12M derived: sum of 2 quarters · filed 2025-02-25 | $5.29M derived: sum of 3 quarters · filed 2025-02-25 | $7.06M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $589.00K derived: sum of 2 quarters · filed 2025-02-25 | $2.36M derived: sum of 3 quarters · filed 2025-02-25 | -$433.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$61.00K derived: sum of 2 quarters · filed 2023-11-06 | -$2.85M 10-Q · filed 2023-11-06 | -$11.79M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.02M 10-Q · filed 2023-08-08 | -$9.96M derived: sum of 3 quarters · filed 2024-02-27 | -$23.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$2.79M 10-Q · filed 2023-05-08 | -$11.73M derived: sum of 2 quarters · filed 2024-02-27 | -$1.79M derived: sum of 3 quarters · filed 2024-02-27 | $4.02M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$8.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $999.00K derived: sum of 2 quarters · filed 2024-02-27 | $6.81M derived: sum of 3 quarters · filed 2024-02-27 | $7.37M 10-K · filed 2024-02-27 |
| 2021-09-30 | $9.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $15.75M derived: sum of 2 quarters · filed 2022-11-07 | $16.31M 10-Q · filed 2022-11-07 | $15.32M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $6.37M 10-Q · filed 2022-08-08 | $5.39M derived: sum of 3 quarters · filed 2023-02-27 | $6.16M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $557.00K 10-Q · filed 2022-05-09 | -$425.00K derived: sum of 2 quarters · filed 2023-02-27 | $351.00K derived: sum of 3 quarters · filed 2023-02-27 | -$336.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$982.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$206.00K derived: sum of 2 quarters · filed 2023-02-27 | -$893.00K derived: sum of 3 quarters · filed 2023-02-27 | $58.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $776.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $89.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.04M 10-Q · filed 2021-11-10 | $1.04M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$687.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $264.00K 10-Q · filed 2021-08-11 | $263.00K derived: sum of 3 quarters · filed 2022-02-28 | $553.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $951.00K 10-Q · filed 2021-05-11 | $950.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.24M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $289.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.07M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.07M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $781.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $378.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |